Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

http://www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Financing Immune Disorders

Takeda Tightens Belt As It Anticipates Difficult 2024, With Growth Returning After

The drug maker has its eye on six Phase III or Phase III-ready programs that it hopes will return the company to growth. It also highlighted investments in AI and digital technology.

Sales & Earnings Business Strategies

Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities

Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.

Deal Watch Business Strategies

Accelerated Approval: Withdrawing Gene Therapies Could Be Easier Than Small Molecules

The FDA would only withdraw a rare disease gene therapy for “pretty clear” reasons, such as when there is minimal benefit with extensive side effects. The one-and-done nature of administration also makes withdrawal easier, CBER Director Peter Marks says.

Gene Therapy Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adaptate Biotherapeutics Ltd
    • Altos Therapeutics LLC
    • AR Scientific, Inc. (URL)
    • ARIAD Pharmaceuticals, Inc.
    • Bradley Pharmaceuticals, Inc
    • Cellerix SA
    • Cerevance, Envoy Therapeutics, Inc.
    • Chordia Therapeutics
    • ChromaJean, Inc.
    • GammaDelta Therapeutics
    • IDM Pharma
    • Intellikine, Inc.
    • Inviragen, Inc.
    • LigoCyte Pharmaceuticals, Inc.
    • Maverick Therapeutics, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Mutual Pharmaceutical Company, Inc. (URL)
    • Neutec
    • Nihon Pharmaceutical Co., Ltd
    • Nycomed Pharma AS
    • Pharmaceutical Holdings Corporation (URL)
    • PvP Biologics, Inc.
    • sanaplasma AG
    • Syrrx, Inc.
    • TAP Pharmaceutical Products, Inc.
    • Teva Takeda Pharma Ltd.
    • Shire Pharmaceuticals Group PLC (SHPG)
    • Teva Takeda Yakuhin Ltd.
    • TiGenix NV
    • URL Pharma, Inc. Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register